Bio-Thera and Avalon Pharma Sign MENA Deal for BAT2406, Proposed Dupixent Biosimilar
China’s Bio-Thera Solutions and Saudi Arabia-based Avalon Pharma have entered into commercialization and license agreements for BAT2406, a proposed biosimilar to Dupixent® (dupilumab), covering Saudi Arabia and the broader Middle East and North Africa…